Eckert & Ziegler and SK Biopharmaceuticals Form Actinium-225 Partnership

Eckert & Ziegler has entered into a strategic supply agreement with SK Biopharmaceuticals to provide Actinium-225, an essential radioisotope in radiopharmaceutical therapies. This partnership aims to bolster SK Biopharmaceuticals' research and development in treating central nervous system disorders and various cancers, including colorectal, breast, pancreatic, and head and neck cancers.

The collaboration will facilitate SK Biopharmaceuticals in advancing their pipeline, notably the SKL35501 radiopharmaceutical therapy. Acquiring a steady supply of Actinium-225 is pivotal for their progress in the global oncology treatment market.

This agreement highlights the significance of sustainable radioisotope sources, where Eckert & Ziegler's expertise in isotopes like Gallium-68 and Lutetium-177 plays a crucial role in supporting pharmaceutical innovations worldwide.